Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

    thumbnails
    Download 2025 Global and China biotech sector survey reports

    Two new reports of surveys of 260+ Global and China biotech leaders have just been released

    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    thumbnail
    ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change

    Watch the webinar.

    data network
    Riding the data wave: How pharma can navigate disruptions in open claims

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Showing 373 - 384 of 955 results for "*"

Social media image
ICON Plc logo
ICON Plc

In this blog from Prof. Peter Schueler, MD, he explores how biomarker innovation is accelerating progress in Alzheimer’s, Parkinson’s, and other CNS trials - bringing new precision, speed, and clarity to a historically c...

19 Nov
Social media image
ICON Plc logo
ICON Plc

ICON supports COPD Awareness Day which takes place on November 19. In the past five years, ICON has participated in 83 respiratory clinical studies including 6 COPD studies, enrolling 6,700+ respiratory patients and heal...

19 Nov
ICON Plc facebook post
ICON Plc logo
ICON Plc

Today is COPD Awareness Day. This year’s theme is ‘Short of Breath, Think COPD’ highlights the importance of recognising symptoms and risk factors. Learn how ICON partners with sponsors, investigators, patients and other...

19 Nov
1
ICON Plc facebook post
ICON Plc logo
ICON Plc

Sponsors face growing pressure to deliver trials that are faster, safer, and more efficient. Holistic risk management is the key. ICON’s latest blog shares insights from Citeline’s panel on how to lead with strategy, not...

19 Nov
1
Social media image
ICON Plc logo
ICON Plc

Sponsors face growing pressure to deliver trials that are faster, safer, and more efficient. Holistic risk management is the key. ICON’s latest blog shares insights from Citeline’s panel on how to lead with strategy, not...

19 Nov
ICON Plc facebook post
ICON Plc logo
ICON Plc

The JCA process is more than a regulatory hurdle—it’s a strategic opportunity. ICON’s whitepaper shows how to turn evidence generation into a competitive advantage. Get the guide: https://ow.ly/2wWF50XgHL8 #JCA #HTA #He...

19 Nov
1
Social media image
ICON Plc logo
ICON Plc

The JCA process is more than a regulatory hurdle—it’s a strategic opportunity. ICON’s whitepaper shows how to turn evidence generation into a competitive advantage. Get the guide: https://ow.ly/2wWF50XgHL8 #JCA #HTA #He...

19 Nov
Social media image
ICON Plc logo
ICON Plc

How do you choose the right control group for organ impairment trials? Despite consensus on the need for demographic similarity between test and control groups, practical guidance is surprisingly scarce. Too often, sele...

19 Nov
Social media image
ICON Plc logo
ICON Plc

Join ICON at #SCDMIndia, taking place 4 – 6 December in Hyderabad! Visit us at booth \#22 to discover how ICON is driving innovation in clinical data management and shaping the future of clinical trials. Don’t miss the c...

19 Nov
ICON Plc facebook post
ICON Plc logo
ICON Plc

Join ICON at #SCDMIndia, taking place 4 – 6 December in Hyderabad! Visit us at booth #22 to discover how ICON is driving innovation in clinical data management and shaping the future of clinical trials. Don’t miss the ch...

19 Nov
2
ICON Plc facebook post
ICON Plc logo
ICON Plc

Did you know the FDA approved its first AI-enabled device in 1995 and now has cleared over 1,000 devices? Yet, there’s still no unique regulatory pathway. Our latest blog explores FDA guidance, lifecycle considerations, ...

18 Nov
4
Social media image
ICON Plc logo
ICON Plc

Did you know the FDA approved its first AI-enabled device in 1995 and now has cleared over 1,000 devices? Yet, there’s still no unique regulatory pathway. Our latest blog explores FDA guidance, lifecycle considerations, ...

18 Nov
  • Previous
  • 1
  • …
  • 31
  • 32
  • 33
  • …
  • 80
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence